35 patents
Utility
Nucleotide Hemi-sulfate Salt for the Treatment of Hepatitis C Virus
18 Jan 24
Adel Moussa, Jean-Pierre Sommadossi
Filed: 23 Jan 23
Utility
BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
4 Jan 24
Jean-Pierre Sommadossi, Adel Moussa
Filed: 23 Jan 23
Utility
Advantageous Morphic Form of AT-527 Hemi-sulfate Salt
16 Nov 23
Advantageous isolated morphic Form III of the hemi-sulfate salt of AT-527 that exhibits a faster rate of dissolution over the amorphous form leading to increased bioavailability and thus efficacy for therapeutic administration in a solid dosage form to treat viral indications, as well as processes for its manufacture.
Adel Moussa
Filed: 25 Jul 23
Utility
Niran Interfering Drugs for SARS-COV-2 Mutant Therapy
16 Nov 23
Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12).
Jean-Pierre Sommadossi, Kai Lin, Adel Moussa, Bruno Canard, Ashleigh Shannon
Filed: 7 Apr 23
Utility
Highly active compounds against COVID-19
14 Nov 23
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 24 Feb 21
Utility
Stereoselective Manufacture of Selected Purine Phosphoramidates
19 Oct 23
Adel Moussa, Narayan Chaudhuri
Filed: 17 Feb 23
Utility
Highly active compounds against COVID-19
25 Jul 23
The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 10 Nov 20
Utility
Treatment of HCV infected patients with cirrhosis
4 Jul 23
Jean-Pierre Sommadossi, Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou
Filed: 7 Oct 20
Utility
Stereoselective Process of Manufacture of Purine Phosphoramidates
16 Feb 23
Adel Moussa
Filed: 21 Oct 22
Utility
2'-SUBSTITUTED-N6-SUBSTITUTED Purine Nucleotides for Rna Virus Treatment
19 Jan 23
The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 22 Sep 21
Utility
Highly Active Compounds Against COVID-19
3 Nov 22
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 24 Feb 21
Utility
Highly Active Compounds Against COVID-19
3 Nov 22
The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 3 May 21
Utility
BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED Purine Nucleotides for HCV Treatment
25 Aug 22
Jean-Pierre Sommadossi, Adel Moussa
Filed: 3 May 21
Utility
Highly Active Compounds Against COVID-19
9 Sep 21
The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 10 Nov 20
Utility
Nucleotide Hemi-sulfate Salt for the Treatment of Hepatitis C Virus
9 Sep 21
Adel Moussa, Jean-Pierre Sommadossi
Filed: 3 May 21
Utility
Nucleotide Hemi-sulfate Salt for the Treatment of Hepatitis C Virus
25 Mar 21
Adel Moussa, Jean-Pierre Sommadossi
Filed: 10 Dec 20
Utility
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
16 Mar 21
The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.
Jean-Pierre Sommadossi, Adel Moussa
Filed: 5 Mar 19
Utility
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
2 Feb 21
Adel Moussa, Jean-Pierre Sommadossi
Filed: 18 Nov 19
Utility
Treatment of HCV Infected Patients with Cirrhosis
21 Jan 21
Jean-Pierre Sommadossi, Adel Moussa, Keith M. Pietropaolo, Xiao-Jian Zhou
Filed: 7 Oct 20
Utility
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
19 Jan 21
Adel Moussa, Jean-Pierre Sommadossi
Filed: 1 Jul 20